Curated News
By: NewsRamp Editorial Staff
June 26, 2024
BenevolentAI and AstraZeneca Collaborate on New Lupus Target
Discuss on Reddit
Discuss on LinkedIn
Discuss on SubstackTLDR
- Adding a novel lupus target enhances AstraZeneca's portfolio, giving them an edge in the competitive pharmaceutical industry.
- The collaboration between BenevolentAI and AstraZeneca focuses on data-driven approach to identify and validate new therapeutic targets for lupus.
- Identifying new therapeutic targets for lupus can lead to improved treatments, offering hope to those suffering from this debilitating autoimmune disease.
- Lupus is a complex autoimmune disease that causes chronic fatigue and organ damage, but new collaborative efforts offer potential breakthroughs in treatment.
Impact - Why it Matters
This news matters as it highlights a significant collaboration between BenevolentAI and AstraZeneca, focusing on the addition of a novel lupus target to AstraZeneca's discovery portfolio. The collaboration aims to identify and validate new therapeutic targets for lupus and other complex diseases, which could lead to potential breakthroughs in treatment.
Summary
BenevolentAI chief scientific officer Dr Anne Phelan discusses the addition of a novel systemic lupus erythematosus (SLE) target to AstraZeneca's discovery portfolio. The collaboration between BenevolentAI and AstraZeneca, which began in 2019, has expanded to include lupus, highlighting the benefits of leveraging data foundations to pull through potential target hypotheses. This collaboration, along with BenevolentAI's data-driven approach and AstraZeneca's disease expertise, facilitates the identification and validation of new therapeutic targets.
Source Statement
This curated news summary relied on this press release disributed by News Direct. Read the source press release here, BenevolentAI and AstraZeneca Collaborate on New Lupus Target
